<DOC>
	<DOCNO>NCT02748811</DOCNO>
	<brief_summary>GERICO randomize , control prospective trial . The aim investigate frail , elderly patient stage II-IV colorectal cancer , profit full comprehensive geriatric assessment intervention treatment chemotherapy . The hypothesis : Optimizing health condition functional status frail elderly patient suffers stage II-IV colorectal cancer , geriatric intervention lead high grade complete plan chemotherapy high dose intensity . This also result high overall survival improve quality life .</brief_summary>
	<brief_title>Effect Geriatric Intervention Frail Elderly Patients Receiving Chemotherapy Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Frail accord screen tool G8 ( ≤14 / 17points ) Performance status 02 life expectancy ≥ 3 month Patients undergone surgery stage III / highrisk stage II colorectal cancer patient unresectable metastatic disease Are assess receive adjuvant chemotherapy first line chemotherapy Meets criterion receive preventive chemotherapy 5FU capecitabine +/ oxaliplatin first line chemotherapy 5FU / irinotecan / oxaliplatin , capecitabine +/ possibly addition immunotherapy form cetuximab , panitumumab bevacizumab . Informed write oral consent Other malignancy except basal cell carcinoma squamous cell carcinoma situ cervicis uteri 5 year Patients simultaneously drug trial The patient must previously receive adjuvant chemotherapy GERICO Protocol</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>elderly</keyword>
	<keyword>intervention study</keyword>
	<keyword>geriatrics</keyword>
	<keyword>chemotherapy</keyword>
</DOC>